Journal of Translational Medicine (May 2022)

Incidence and immunomic features of apyretic COVID-19 in patients affected by solid tumors: a prospective cohort study

  • Francesco Ravera,
  • Roberto Borea,
  • Gabriella Cirmena,
  • Martina Dameri,
  • Lorenzo Ferrando,
  • Maurizio Gallo,
  • Cecilia Casini,
  • Neri Fallani,
  • Mario Stabile,
  • Valentina Barbero,
  • Roberto Murialdo,
  • Lucia Tixi,
  • Margherita Cappuccio,
  • Andrea Cuboni,
  • Irene Sivieri,
  • Giuseppe Fornarini,
  • Andrea De Maria,
  • Alberto Ballestrero,
  • Gabriele Zoppoli

DOI
https://doi.org/10.1186/s12967-022-03429-0
Journal volume & issue
Vol. 20, no. 1
pp. 1 – 11

Abstract

Read online

Abstract Background and rationale Little is known about SARS-CoV-2 seroconversion in asymptomatic patients affected by solid cancer, and whether it is associated with specific transcriptomics changes in peripheral blood mononuclear cells (PBMC). Methods Patients affected by solid cancer treated in a top comprehensive cancer center in Italy during the first COVID-19 pandemic wave, and negative for COVID-19-symptoms since the first detection of COVID-19 in Italy, were prospectively evaluated by SARS-CoV-2 serology in the period between April 14th and June 23rd 2020. Follow-up serologies were performed, every 21–28 days, until August 23rd 2020. All SARS-CoV-2 IgM + patients underwent confirmatory nasopharyngeal swab (NPS). PBMCs from a subset of SARS-CoV-2 IgM + patients were collected at baseline, at 2 months, and at 7 months for transcriptome sequencing. Results SARS-CoV-2 serology was performed on 446 of the 466 recruited patients. A total of 14 patients (3.14%) tested positive for at least one SARS-CoV-2 immunoglobulin in the period between April 14th and August 23rd 2020. Incidence of SARS-CoV-2 IgM decreased from 1.48% in the first month of the accrual to 0% in the last month. Viral RNA could not be detected in any of the NPS. PBMC serial transcriptomic analysis showed progressive downregulation of interleukin 6 upregulated signatures, chemokine-mediated signaling and chemokine-chemokine receptor KEGG pathways. B- and T-cell receptor pathways (p-values = 0.0002 and 0.017 respectively) were progressively upregulated. Conclusions SARS-CoV-2 seroconversion rate in asymptomatic patients affected by solid cancer is consistent with that of asymptomatic COVID-19 assessed in the general population through NPS at the peak of the first wave. Transcriptomic features over time in IgM + asymptomatic cases are suggestive of previous viral exposure.

Keywords